Reaction

Limb Mass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,160 reports · 44 co-occurring drugs

As of the last recalculation, Limb Mass appears in 2,160 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED (PRR 18.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Diphenhydramine Hydrochloride Capsule, Liquid Filled	41	18.8	18.9
Meperidine Hydrochloride	17	17.9	17.9
Vemurafenib	20	16.2	16.2
Desoximetasone	27	13.8	13.8
Dimenhydrinate	15	13.7	13.7
Atropine	11	12.9	12.9
Tocilizumab	139	12.5	12.5
Rabeprazole	26	11.4	11.4
Rizatriptan Benzoate	12	11.4	11.4
Hydrocortisone Sodium Succinate	11	11.3	11.3
Human Immunoglobulin G	23	10.8	10.9
Sucralfate Oral	15	10.2	10.2
Sucralfate Oral Suspension	15	10.2	10.2
Infliximab-Dyyb	30	10.0	10.0
Atropine Sulfate	11	9.9	9.9
Asfotase Alfa	10	9.7	9.7
Moxifloxacin	13	8.9	8.9
Moxifloxacin Hydrochloride	18	8.6	8.6
Zinc Gluconate	21	7.8	7.8
Diphenhydramine	47	7.3	7.3
Meloxicam	37	6.2	6.2
Quinapril Hydrochloride	5	6.1	6.1
Cladribine	6	6.0	6.0
Upadacitinib	45	5.4	5.4
Risankizumab-Rzaa	43	5.2	5.2
Adalimumab	318	4.9	4.9
Acalabrutinib	6	4.8	4.8
Pirfenidone	20	4.8	4.8
Peginterferon Beta-1A	6	4.4	4.4
Cetuximab	13	4.0	4.0
Naltrexone	12	3.8	3.8
Cannabidiol	9	3.7	3.7
Dofetilide	4	3.7	3.7
Abatacept	50	3.5	3.5
Interferon Beta-1B	7	3.5	3.5
Ocrelizumab	22	3.4	3.4
Tofacitinib	63	3.4	3.4
Alpelisib	3	3.3	3.3
Diroximel Fumarate	4	3.2	3.2
Emicizumab	4	3.1	3.1
Abaloparatide	9	3.0	3.0
Ixekizumab	7	1.8	1.8
Evolocumab	18	1.1	1.1
Salicylic Acid	5	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.